PRTG Soars On Mesothelioma Data, NVNO Awaits FDA Decision, CureVac Jumps On Patent News

CureVac

2.78 CHF 5.43%

• Charts
• News
• Analysen

Kaufen Verkaufen

(RTTNews) - The following are some biotech stocks you should keep an eye on today - Friday, March 28, 2025.

Shares of Portage Biotech Inc. (PRTG) were up over 100% in after-hours trading on Thursday, following promising preclinical data for PORT-7, a selective Adenosine A2B receptor inhibitor, given as a single agent or in combination with anti-PD-1 antibody in a murine model of mesothelioma. There was more than 90% tumor growth inhibition when PORT-7 was combined with an anti-PD1 antibody in preclinical testing. A 1-for-20 reverse stock split was implemented by the company on August 15, 2024.

PRTG closed Thursday's trading at $4.71, up 5.84%. In after-hours, the stock was up over 106% at $9.74.

Sensei Biotherapeutics Inc. (SNSE) has reported favorable initial results from the dose expansion portion of its Phase 1/2 trial evaluating Solnerstotug as monotherapy and in combination with Regeneron's PD-1 inhibitor, Libtayo, in both a basket of "hot" tumors that typically respond to immunotherapy but have progressed on prior PD-(L)1 therapy and a single "cold" tumor histology that is typically unresponsive to immunotherapy. The hot tumors studied in the trial include Non-Small Cell Lung Cancer (NSCLC), Head and Neck (H&N) cancer, Melanoma, Renal Cell Carcinoma (RCC), Merkel Cell Carcinoma (MCC), MSI-H Colorectal Cancer (CRC), and other tumor types while the only "cold" tumor histology explored is microsatellite stable (MSS) Colorectal Cancer. According to the trial results, 14% Overall Response Rate (ORR) and 62% disease control rate were observed among 21 evaluable PD-(L)1 resistant "hot" tumor patients. The company added that the initial 14% response rate seen with Solnerstotug is nearly three times higher than what would typically be expected in this setting.

SNSE closed Thursday's trading at $0.43, down 1.19%. In after-hours trading, the stock was up 40.41% at $0.60.

TransCode Therapeutics Inc. (RNAZ), on Thursday, announced that the first patient in Cohort 4 of its Phase I clinical trial in patients with a variety of metastatic solid cancers has received their initial dose of TTX-MC138. Two more patients in Cohort 4 are scheduled to receive TTX-MC138. The lead candidate, TTX-MC138, is designed to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer.

RNAZ closed Thursday's trading at $0.52, down 11.86%. In after-hours, the stock was up 28.85% at $0.67.

Prelude Therapeutics Inc. (PRLD), a clinical-stage precision oncology company, was up over 23% in after-hours trading Thursday on no specific news. Its lead drug candidate is PRT3789, designed to treat patients with SMARCA4-mutated cancer, a particularly aggressive form of the disease. An interim data update from a phase I trial of PRT3789 is anticipated in the second half of 2025. A Phase 2 clinical trial evaluating PRT3789 in combination with Merck's KEYTRUDA in patients with SMARCA4-mutated cancers is also underway.

PRLD closed Thursday's trading at $0.68, up 6.61%. In after-hours, the stock was up 23% at $0.83.

enVVeno Medical (NVNO), a late clinical-stage medical device company, has a regulatory catalyst to watch in the coming months. The company has sought FDA approval for its investigational device VenoValve and a decision is anticipated in the second half of this year. VenoValve, which has been designated as a breakthrough device by the FDA, is intended to treat severe deep venous Chronic Venous Insufficiency (CVI), a debilitating disease that is most often caused by blood clots (deep vein thromboses or DVTs) in the deep veins of the leg.

NVNO closed Thursday's trading at $2.83, down 2.41%. In after-hours, the stock was up 10% at $3.13.

Kezar Life Sciences, Inc. (KZR) recently reported positive topline results from its phase IIa trial evaluating Zetomipzomib, a novel, first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis, dubbed PORTOLA. In the intention-to-treat (ITT) population, 5 of 16 (31%) Zetomipzomib patients achieved a Complete Response and steroid taper, compared to 1 of 8 placebo patients.

KZR closed Thursday's trading at $5.13, down 0.77%. In after-hours, the stock was up 7.21% at $5.50.

CureVac N.V.'s (CVAC) European patent EP 3 708 668 B1 subject to amendments, pioneering mRNA innovation, has been validated by the European Patent Office. EP 3 708 668 B1 describes a foundational invention of CureVac, called split poly-A tail technology, which enhances medical efficacy by improving the expression of the protein encoded on an mRNA construct. The patent's validity was challenged by BioNTech SE in April 2023. CureVac and BioNTech are embroiled in patent suits in Germany, which involve a total of six intellectual property rights. Following the decision of the European Patent Office, the Regional Court Düsseldorf will decide whether the patent in its amended form has been infringed. An infringement hearing is scheduled for July 1, 2025.

CVAC closed Thursday's trading at $2.80, down1.75%. In after-hours, the stock was up 7.14% at $3.00.